Standard BioTools Inc. Purchase Obligation, to be Paid, Year One
Standard BioTools Inc. (LAB) had Purchase Obligation, to be Paid, Year One of $16.20 million as of 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:PurchaseObligationDueInNextTwelveMonths · last filed 2024-11-06
- 2024-09-30: Purchase Obligation, to be Paid, Year One $16.20M.
- 2024-06-30: Purchase Obligation, to be Paid, Year One $18.50M.
- 2024-03-31: Purchase Obligation, to be Paid, Year One $21.60M.
- 2023-12-31: Purchase Obligation, to be Paid, Year One $9.70M.
| Period end | Purchase Obligation, to be Paid, Year One |
|---|---|
| 2024-09-30 | $16.20M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $18.50M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $21.60M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $9.70M 10-K · filed 2024-03-01 |
| 2022-12-31 | $13.50M 10-K · filed 2023-03-14 |
| 2021-12-31 | $22.00M 10-K · filed 2022-03-08 |
| 2020-12-31 | $12.90M 10-K · filed 2021-02-25 |
| 2019-12-31 | $2.20M 10-K · filed 2020-02-27 |
| 2018-12-31 | $1.60M 10-K · filed 2019-03-18 |
| 2017-12-31 | $1.30M 10-K · filed 2018-03-08 |
| 2016-12-31 | $4.20M 10-K · filed 2017-03-03 |
| 2015-12-31 | $8.50M 10-K · filed 2016-02-29 |
| 2014-12-31 | $9.10M 10-K · filed 2015-02-26 |
| 2013-12-31 | $8.60M 10-K · filed 2014-03-12 |
| 2012-12-31 | $3.90M 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |